Inside the Psoriatic Arthritis Treatment Market: Top Innovators
Market Growth
The global psoriatic arthritis treatment market size is calculated at USD 10.91 billion in 2025, grew to USD 11.94 billion in 2026, and is projected to reach around USD 26.76 billion by 2035. The market is expanding at a CAGR of 9.44% between 2026 and 2035.
Company Landscape
AbbVie Inc.
Company Overview: A global, research-based biopharmaceutical company focused on developing and commercializing advanced therapies, with Immunology as its largest and most strategic revenue-driving franchise. It is actively and successfully navigating the loss of exclusivity for Humira by aggressively growing its next-generation PsA treatments.
Corporate Information:
- Headquarters: North Chicago, Illinois, USA
- Year Founded: 2013 (Spun off from Abbott Laboratories)
- Ownership Type: Public (NYSE: ABBV)
History and Background: Established as an independent entity focused on specialty pharmaceuticals. Its history is defined by the massive success of Humira (adalimumab) in the PsA and autoimmune space. The current phase is marked by a focus on diversifying and driving market adoption of its successor products, Skyrizi and Rinvoq.
Key Milestones/Timeline:
- 2020: Acquired Allergan, significantly diversifying its therapeutic and aesthetic portfolio.
- 2023-2025: Successfully executed the commercial strategy to offset Humira biosimilar entry by achieving explosive sales growth for its next-generation immunology assets.
- June 2024: RINVOQ approved for pediatric PsA patients (2 years and older) in the U.S.
- April 2025: RINVOQ received U.S. FDA approval for Giant Cell Arteritis (GCA).
- Business Overview: Focuses on delivering innovative treatments for complex and serious diseases. The company reported global net revenues of $15.776 billion for Q3 2025, with the Immunology portfolio generating $7.885 billion, an increase of 11.9% year-over-year.
- Business Segments/Divisions: Immunology (Core to PsA market), Oncology, Neuroscience, and Aesthetics.
- Geographic Presence: Maintains a significant operational presence across more than 175 countries, with the largest market shares in North America and key European countries.
Key Offerings:
- Biologics: Skyrizi (risankizumab, an IL-23 inhibitor); Humira (adalimumab, a TNF inhibitor, declining due to biosimilar competition).
- Oral Small Molecule: Rinvoq (upadacitinib, a JAK inhibitor).
- End-Use Industries Served: Specialty Clinics (Rheumatology, Dermatology), Hospitals, and Specialty Pharmacies.
Key Developments and Strategic Initiatives:
- Aggressively pushing the commercial transition to Skyrizi (Q3 2025 sales: $4.708 billion) and Rinvoq (Q3 2025 sales: $2.184 billion) to drive the new growth platform.
- Successfully raised its full-year 2025 Adjusted Diluted EPS Guidance to $10.61 - $10.65 based on strong demand for its immunology treatments.
Mergers & Acquisitions:
- Aug 2025: Completed the acquisition of Capstan Therapeutics, further strengthening the Immunology and Oncology pipeline with in vivo cell therapy capabilities.
- Jan 2025: Completed the acquisition of Nimble Therapeutics to enhance its drug discovery efforts.
Partnerships & Collaborations:
Feb 2024: Collaboration with Tentarix to develop conditionally-active, multi-specific biologics for both Oncology and Immunology.
Product Launches/Innovations:
- June 2024: RINVOQ launched for pediatric Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis patients in the U.S.
- Ongoing clinical trials for pipeline assets like Lutikizumab for Hidradenitis Suppurativa, showing positive Phase 2 results (Jan 2024).
Capacity Expansions/Investments:
Announced plans for a $195 million investment in a new U.S. manufacturing facility, part of a $10 billion decade-long strategy to expand U.S. biopharmaceutical manufacturing capabilities.
Regulatory Approvals:
- April 2025: RINVOQ received U.S. FDA approval for Giant Cell Arteritis (GCA).
- June 2024: SKYRIZI received U.S. FDA approval for Ulcerative Colitis.
- Distribution channel strategy: Relies on a managed distribution model primarily utilizing Specialty Pharmacies to handle the high cost, specialized patient management, and administration of its biologic and JAK inhibitor drugs.
Technological Capabilities/R&D Focus:
- Focus: Next-generation targeted therapies, specifically highly selective IL-23 inhibition (Skyrizi) and JAK1 inhibition (Rinvoq) to offer differentiated efficacy and patient convenience.
- Core Technologies/Patents: Monoclonal antibody technology and proprietary Janus Kinase (JAK) selective inhibition technology.
- Research & Development Infrastructure: Maintains an extensive global R&D network, with adjusted R&D expense standing at 14.3% of net revenues in Q3 2025.
- Innovation Focus Areas: Advancing oral small molecules and targeted biologics that offer superior efficacy and durability to address unmet needs in autoimmune diseases.
- Competitive Positioning: Holds a dominant position in the PsA market through a successful portfolio transition, positioning its newest drugs as the preferred options following the failure of older TNF inhibitors.
Strengths & Differentiators:
- Robust Portfolio: Offers multiple, high-efficacy mechanisms (IL-23, JAK) for tailored treatment.
- Strong Financial Growth: High sales of successor drugs successfully absorbing the impact of biosimilar competition.
- Market presence & ecosystem role: A dominant industry player, setting market standards for commercial strategy and patient support programs in the autoimmune field.
SWOT Analysis:
- Strengths: Leading Immunology Franchise (Skyrizi/Rinvoq); High R&D investment.
- Weaknesses: Continued decline of Humira revenue; Safety warnings associated with JAK inhibitors (Rinvoq).
- Opportunities: Global expansion of Skyrizi/Rinvoq; Pipeline drugs for other immune conditions (e.g., Alopecia Areata, Vitiligo).
- Threats: Increasing competition from rival IL-23/TYK2 inhibitors; Pricing pressure on biologics.
Recent News and Updates:
- Oct 31, 2025: Reported strong Q3 2025 financial results, raising full-year profit forecast due to Skyrizi and Rinvoq outperformance.
- Oct 29, 2025: Announced positive topline results from Phase 3 studies evaluating RINVOQ in adults and adolescents with Vitiligo.
Press Releases:
- Oct 31, 2025: AbbVie Reports Third-Quarter 2025 Financial Results, highlighting Global Skyrizi net revenues of $4.708 billion and Global Rinvoq net revenues of $2.184 billion in the quarter.
- Industry Recognitions/Awards: Consistently recognized as a global leader in biopharma innovation, particularly for advancements in immunology.
Johnson & Johnson Services, Inc. (Janssen Pharmaceutical Companies)
Company Overview: A focused global healthcare company specializing in Innovative Medicine (Janssen) and MedTech. The Janssen division is a major force in the PsA market, focused on immunology, oncology, and neuroscience.
Corporate Information:
- Headquarters: New Brunswick, New Jersey, USA
- Year Founded: 1886
- Ownership Type: Public (NYSE: JNJ)
History and Background: Long history as a diversified healthcare giant. Janssen's immunology success was pioneered with Remicade and solidified with the launch of Stelara and the next-generation Tremfya, maintaining a key competitive edge in autoimmune diseases. The company fully separated its Consumer Health business (Kenvue) in 2023 to sharpen its focus on Innovative Medicine and MedTech.
Key Milestones/Timeline:
- 2017: TREMFYA (guselkumab) received initial US FDA approval.
- 2023: Completed the separation of the Consumer Health business (Kenvue).
- July 2025: Submitted a New Drug Application (NDA) to the U.S. FDA for its oral targeted peptide icotrokinra (JNJ-2113) for plaque psoriasis, which is also in Phase 3 for PsA.
- Business Overview: The Innovative Medicine segment drives the company's growth, with reported revenues of $88.82 billion in 2024. Immunology, driven by its PsA treatments, is a top-performing franchise.
- Business Segments/Divisions: Innovative Medicine (Janssen - Includes PsA treatments), MedTech.
- Geographic Presence: Operates and serves patients worldwide, with a powerful presence across North America, Europe, and the Asia Pacific.
Key Offerings:
- Biologics: STELARA (ustekinumab, an IL-12/23 inhibitor); TREMFYA (guselkumab, an IL-23 inhibitor).
- Pipeline Oral Peptide: icotrokinra (JNJ-2113, a targeted oral IL-23 receptor antagonist) currently in Phase 3 trials for PsA.
- End-Use Industries Served: Hospitals, Specialty Clinics, Rheumatology and Dermatology Practices, Specialty Pharmacies.
Key Developments and Strategic Initiatives:
- Aggressive late-stage development of the oral targeted peptide icotrokinra, a potential first-in-class, non-injectable, selective IL-23 blocker intended to capture the large market segment seeking oral convenience.
- Focusing on label expansions and real-world data to demonstrate the durable efficacy of TREMFYA across multiple immune-mediated diseases.
- Mergers & Acquisitions: Has historically focused on targeted acquisitions, such as the initial agreement with Protagonist Therapeutics (2017) that led to the development of icotrokinra.
Partnerships & Collaborations:
- Feb 2024: Announced a settlement and licensing agreement with Biocon Biologics to manage the commercialization of a Stelara biosimilar in the US.
- Ongoing co-development and licensing agreement with Protagonist Therapeutics for icotrokinra.
Product Launches/Innovations:
- July 2025: Submitted NDA for the oral peptide icotrokinra for plaque psoriasis, with PsA filings expected soon after based on the ongoing ICONIC-PSA 1 and 2 Phase 3 studies.
- Capacity Expansions/Investments: Maintained consistently high R&D investment, prioritizing advanced immunology platforms like the oral targeted peptide technology.
Regulatory Approvals:
- Oct 2025: Presented new 96-week data at ACG 2025 showing TREMFYA achieves durable remission in Crohn's disease, reinforcing its broad utility across immune conditions, including PsA.
- July 2025: NDA submitted for icotrokinra in plaque psoriasis.
- Distribution channel strategy: Utilizes a sophisticated global distribution network focused on Specialty Pharmacies and hospital/infusion centers for its injectable biologics, complemented by comprehensive patient support and adherence programs.
Technological Capabilities/R&D Focus:
- Focus: Highly selective IL-23 inhibition (Tremfya) and the development of the first-in-class oral targeted peptide (icotrokinra) to precisely block the IL-23 receptor.
- Core Technologies/Patents: Monoclonal antibody technology targeting interleukins (IL-23) and patented oral peptide technology for targeted immune modulation.
- Research & Development Infrastructure: Extensive global infrastructure under Janssen, with the ICONIC program (for icotrokinra) representing a massive investment across multiple immune indications, including PsA.
- Innovation Focus Areas: Leading the push toward oral targeted biologics (icotrokinra) and maximizing the clinical differentiation of TREMFYA, which is noted for its ability to inhibit joint structural damage in PsA.
- Competitive Positioning: A strong, entrenched market competitor that successfully transitioned from the TNF era to the IL-23 inhibitor class. The potential launch of the oral peptide icotrokinra could be a major competitive disruptor.
Strengths & Differentiators:
- Highly Effective Biologic: TREMFYA offers a quarterly subcutaneous injection schedule and strong efficacy across all PsA domains.
- Pipeline Innovation: Leading the development of a potential first-in-class oral IL-23 receptor antagonist (icotrokinra).
- Market presence & ecosystem role: A historic leader in autoimmune disease treatment, heavily influencing clinical guidelines and standard of care for PsA and psoriasis.
SWOT Analysis:
- Strengths: Established, high-performing IL-23 inhibitor (Tremfya); Highly promising late-stage oral pipeline asset (icotrokinra).
- Weaknesses: Facing biosimilar erosion for the older anchor drug Stelara.
- Opportunities: Launch of icotrokinra to capture the oral therapy market; Further clinical data demonstrating Tremfya's long-term durability.
- Threats: High-efficacy competition from AbbVie's Skyrizi/Rinvoq and newer TYK2 inhibitors.
Recent News and Updates:
- Oct 27, 2025: Presented new 96-week data on TREMFYA showing durable remission in Crohn's disease, confirming its long-term efficacy across related immune conditions.
- Oct 27, 2025: Announced that icotrokinra maintains a strong therapeutic benefit and favorable safety profile in ulcerative colitis through 28 weeks, reinforcing its high potential for PsA.
Press Releases:
- July 2025: Submitted NDA for icotrokinra to the U.S. FDA.
- Industry Recognitions/Awards: Recognized among the top pharmaceutical companies for R&D spending and innovation.
Value Chain Analysis - Psoriatic Arthritis Treatment Market
R&D
Researchers are focusing on better understanding the pathophysiology of PsA to develop targeted treatments. Novel biomarkers are identified to derive biologics for personalized treatments.
Key Players: Bristol Myers Squibb, Amgen, Inc., and UCB.
Clinical Trials & Regulatory Approval
Clinical trials are conducted to assess the safety and efficacy of PsA therapeutics. These therapeutics are then subsequently approved by several regulatory agencies.
Key Players: MoonLake Immunotherapeutics AG, Novartis Pharmaceuticals, Hansoh BioMedical R&D Company, and ACELYRIN Inc.
Patient Support & Services
Patient support & services refer to regular monitoring and lifestyle changes like exercise and stress management. It also includes reimbursement for treatment regimens.
Recent Developments in the Psoriatic Arthritis Treatment Market
- In June 2025, Bristol Myers Squibb reported positive results from its Phase 3 POETYK PsA-1 trial that assesses Sotyktu (deucravacitinib) to improve symptoms in adults with active PsA compared to placebo. Approximately 54.2% of patients receiving Sotyktu achieved a 20% improvement in signs and symptoms in PsA.
- In May 2025, Biocon Biologics Ltd. announced that its commercial partner, Yoshindo, Inc., launched Ustekinumab BS Subcutaneous Injection, a biosimilar to Stelara. The drug is approved for the treatment of psoriasis vulgaris and PsA. It was launched in the U.S. and European markets in February 2025.
Partner with our experts to explore the Psoriatic Arthritis Treatment Market at sales@towardshealthcare.com
